Literature DB >> 21278220

Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls.

J Bellmunt, T K Choueiri, F A B Schutz, J E Rosenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21278220     DOI： 10.1093/annonc/mdq684

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.

Authors:  Toni K Choueiri; Robert W Ross; Susanna Jacobus; Ulka Vaishampayan; Evan Y Yu; David I Quinn; Noah M Hahn; Thomas E Hutson; Guru Sonpavde; Stephanie C Morrissey; Geoffrey C Buckle; William Y Kim; Daniel P Petrylak; Christopher W Ryan; Mario A Eisenberger; Amir Mortazavi; Glenn J Bubley; Mary-Ellen Taplin; Jonathan E Rosenberg; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

Review 2.  Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.

Authors:  Ahmet Murat Aydin; Solomon L Woldu; Ryan C Hutchinson; Martin Boegemann; Aditya Bagrodia; Yair Lotan; Vitaly Margulis; Laura-Maria Krabbe
Journal:  Onco Targets Ther       Date:  2017-03-09       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.